Answers are grounded in this paper and cite their sources.
Investigates oral site-specific patch testing outcomes in drug allergy diagnosis, suggesting efficacy of targeted approach.
The authors declare no conflicts of interest. Data sharing not applicable to this article as no datasets were generated or analysed during the current study. Figure S1: Conventional patch testing on uninvolved back skin. Conventional patch testing on uninvolved back skin with etoricoxib 10%, etoricoxib 30%, celecoxib 10%, and celecoxib 30% showed no reaction at 48 and 96 h. Vehicle control was also negative. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
No takes yet. Share an insight, caveat, or question.
Chumsaengchotsakul et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: